Literature DB >> 15591026

PTTG's C-terminal PXXP motifs modulate critical cellular processes in vitro.

K Boelaert1, R Yu, L A Tannahill, A L Stratford, F L Khanim, M C Eggo, J S Moore, L S Young, N J L Gittoes, J A Franklyn, S Melmed, C J McCabe.   

Abstract

Human pituitary tumor-transforming gene (PTTG), known also as securin, is a multifunctional protein implicated in the control of mitosis and the pathogenesis of thyroid, colon, oesophageal and other tumour types. Critical to PTTG function is a C-terminal double PXXP motif, forming a putative SH3-interacting domain and housing the gene's sole reported phosphorylation site. The exact role of phosphorylation and PXXP structure in the modulation of PTTG action in vitro remains poorly understood. We therefore examined the mitotic, transformation, proliferation and transactivation function of the C-terminal PXXP motifs of human PTTG. Live-cell imaging studies using an EGFP-PTTG construct indicated that PTTG's regulation of mitosis is retained regardless of phosphorylation status. Colony-formation assays demonstrated that phosphorylation of PTTG may act as a potent inhibitor of cell transformation. In proliferation assays, NIH-3T3 cells stable transfected and overexpressing mutations preventing PTTG phosphorylation (Phos-) showed significantly increased [3H]thymidine incorporation compared with WT, whereas mutants mimicking constitutive phosphorylation of PTTG (Phos+) exhibited reduced cell proliferation. We demonstrated that PTTG transactivation of FGF-2 in primary thyroid and PTTG-null cell lines was not affected by PTTG phosphorylation but was prevented by a mutant disrupting the PXXP motifs (SH3-). Taken together, our data suggest that PXXP structure and phosphorylation are likely to exert independent and critical influences upon PTTG's diverse actions in vitro.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15591026     DOI: 10.1677/jme.1.01606

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  4 in total

1.  Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins.

Authors:  Sudhakar Chintharlapalli; Sabitha Papineni; Syng-Ook Lee; Ping Lei; Un Ho Jin; Steven I Sherman; Libero Santarpia; Stephen Safe
Journal:  Mol Carcinog       Date:  2011-01-25       Impact factor: 4.784

2.  A single amino acid substitution (Cys249Trp) in Crb1 causes retinal degeneration and deregulates expression of pituitary tumor transforming gene Pttg1.

Authors:  Serge A van de Pavert; Jan Meuleman; Anna Malysheva; Wendy M Aartsen; Inge Versteeg; Felix Tonagel; Willem Kamphuis; Chris J McCabe; Mathias W Seeliger; Jan Wijnholds
Journal:  J Neurosci       Date:  2007-01-17       Impact factor: 6.167

3.  Monocarboxylate transporter 8 expression in the human placenta: the effects of severe intrauterine growth restriction.

Authors:  S-Y Chan; J A Franklyn; H N Pemberton; J N Bulmer; T J Visser; C J McCabe; M D Kilby
Journal:  J Endocrinol       Date:  2006-06       Impact factor: 4.286

4.  PTTG: an important target gene for ovarian cancer therapy.

Authors:  Siva Kumar Panguluri; Casey Yeakel; Sham S Kakar
Journal:  J Ovarian Res       Date:  2008-10-20       Impact factor: 4.234

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.